Aastrom Biosciences

Developing Cell Therapy Treatments for Severe Cardiovascular Disease

Aastrom colleagues are working every day to help people with severe, chronic cardiovascular disease realize the promise of cellular therapy. Our cellular therapy, ixmyelocel-T, draws on the human body’s own natural healing powers. Ixmyelocel-T is a patient-specific, expanded multicellular therapy produced from Aastrom’s proprietary technology.

Aastrom is developing ixmyelocel-T to treat patients with severe, chronic cardiovascular diseases, including critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). We have initiated a pivotal Phase 3 clinical trial (REVIVE) for patients with critical limb ischemia and who have no option for revascularization in Q4 2011. To be a part of this clinical study, or to learn more about CLI, visit revivecli.com and find out about this new investigational treatment. Contact us to learn more about Aastrom and the development of our patient-specific, multicellular therapies.